ArticleCancer science2018

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.

Chengying Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.